News

Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...
Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...
Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...
Sally Susman helped steer Pfizer through COVID-19. Her advice for leaders? Learn to write — and listen.
Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.
Pfizer, Inc. (NYSE: PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer, Inc. (NYSE:PFE) have announced a direct-to-patient program for ...
The global prostate cancer treatment market size is expected to be worth around 34.28 billion by 2034, increasing from USD 16.05 billion in 2025, representing a healthy CAGR of 8.8% from 2025 to 2034.
Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to cash-paying U.S. patients at a discount to its listed price as drugmakers ...
Bristol Myers Squibb and Pfizer are launching a direct-to-patient program with 40% discount on Eliquis, reducing the monthly cost from $606 to $346 for eligible patients.
Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount.
Pfizer’s multi-year effort to stabilize its U.S. penicillin supply has hit an unexpected hitch after particulate concerns prompted a recall of the company’s long-acting injectable form of the ...